Cargando…
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
Vandetanib (ZD6474) became the first systemic agent to be approved for the treatment of metastatic or locally advanced medullary thyroid cancer. It was a proof of principle, because it is an orally bioavailable medication that targets the growth factors felt to be important in the pathogenesis of th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255572/ https://www.ncbi.nlm.nih.gov/pubmed/22241953 http://dx.doi.org/10.2147/OTT.S17422 |